TITLE

Pharmacology of Heart Failure in 2001

AUTHOR(S)
LeBlanc, Marie-Hélène
PUB. DATE
June 2001
SOURCE
Clinical & Investigative Medicine;Jun2001 Supplement, Vol. 24, pS12
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the pharmacological treatment of chronic congestive heart failure (CHF). The pharmacological treatment of CHF due to left ventricular systolic dysfunction has undergone rapid changes during the past years. Heart failure in considered a neurohormonal disorder that is inadequately controlled by standard therapy with ACE inhibitors, diuretics and digitalis.
ACCESSION #
23218912

 

Related Articles

  • Digitalis Pharmacology and Therapeutics: Recent Advances. Mason, Dean T. // Annals of Internal Medicine;Apr74, Vol. 80 Issue 4, p520 

    Discusses the advances in digitalis pharmacology and therapeutics as of 1974. Fundamental therapeutic action of digitalis; Reason for the beneficial effects of digitalis in patients with congestive heart failure; Cardiocirculatory effects in congestive heart failure.

  • Digitalis for Treatment of Congestive Heart Failure in Patients in Sinus Rhythm. Cayley Jr., William E. // American Family Physician;1/1/2004, Vol. 69 Issue 1, p71 

    Examines the effectiveness of digitalis glycosides in treating congestive heart failure in patients with normal sinus rhythm. Medical history of the patient; Interaction of digitalis with angiotensin-converting enzyme inhibitors; Guidelines on evaluation and management of heart failure.

  • Candesartan Plus ACE Inhibitor for CHF. Barry, Henry // American Family Physician;1/1/2004, Vol. 69 Issue 1, p164 

    Studies the effects of candesartan in patients with congestive heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors. Clinical setting of the study; Study design; Discussion on the result of the study.

  • Digitalis-like Compounds: the Discovery of the O-aminoalkyloxime Group as a Very Powerful Substitute for the Unsaturated γ-Butyrolactone Moiety. Gobbini, Mauro; Cerri, Alberto // Current Medicinal Chemistry;2005, Vol. 12 Issue 20, p2343 

    Digitalis compounds are used in the treatment of congestive heart failure as positive inotropic agents; their action is mainly due to the inhibition of the Na+,K+-ATPase. A well-known drawback is their arrhythmogenic potential together with a low therapeutic index. Digitalis compounds are...

  • DIGITALIS PREPARATIONS (Digitalis Glycosides).  // Complete Guide to Prescription & Nonprescription Drugs 2012;2008, p318 

    The article presents information on digitalis preparations, a class of digitalis glycosides used for the treatment of congestive heart failure. The dosage and usage information is provided. The possible adverse reactions or side effects of the drug, warnings, and precautions are discussed....

  • Update on Digoxin Therapy in Congestive Heart Failure. Haji, Showkat A.; Movahed, Assad // American Family Physician;7/15/2000, Vol. 62 Issue 2, p409 

    Congestive heart failure is a progressive disease with significant morbidity and mortality. Despite advances in the prevention and treatment of cardiovascular diseases, the incidence and prevalence of congestive heart failure have increased in recent years. Contributing factors include increased...

  • Reevaluation of Digitalis Efficacy. Mulrow, Cynthia D.; Feussner, John R.; Valez, Ramon // Annals of Internal Medicine;Jul84, Vol. 101 Issue 1, p113 

    Presents information on a study which reevaluated the efficacy of digitalis as a treatment for patients with congestive heart failure and sinus rhythm. Methodology of the study; Results; Conclusions and therapeutic recommendations.

  • Most congestive heart failure patients aren't taking ACE inhibitors. Leibovitch, Eric R. // Modern Medicine;Feb98, Vol. 66 Issue 2, p31 

    Discusses the abstract `National Patterns of Angiotensin-Converting Enzyme Inhibitor Use in Congestive Heart Failure,' by R.S. Stafford, D. Saglam and D. Blumenthal which appeared in the November 24, 1997 issue of `Archives of Internal Medicine.'

  • Angiotensin II Antagonist Had No Survival Benefit over an ACE Inhibitor in Elderly Patients with Congestive Heart Failure but Was Better Tolerated. B., Pitt; P.A., Poole-Wilson; R., Segal; Frishman, William H. // Annals of Internal Medicine;9/18/2001, Vol. 135 Issue 6, p443 

    Compares the efficacy of angiotensin II antagonists and angiotensin converting enzyme (ACE) inhibitors in treating congestive heart failure. Effects of ACE inhibitors on bradykinin levels; Estimation of the average annual rates of all-cause mortality; Elimination of the cough in a patient taking...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics